StockData

Immunome vs Marker Therapeutics

IMNM and MRKR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMNM and MRKR compare

Immunome is the larger company, worth 140 times as much as Marker Therapeutics ($2.0B against $13.9M).

Immunome scores higher on the StockData Score (7 against 6 for Marker Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMNMMRKR
Size and price
Market cap$2.0B$13.9M
Share price$17.18$0.837
Change, 1 year0.23%−9.4%
Change, 5 years1.2%−93.2%
Beta (5Y)1.621.92
Employees1775
StockData Score
Total score7 (better)6
Valuation score01 (better)
Growth score00
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S486×–
P/B3.3×1.1× (better)
FCF yield−10.5%–
Growth
Revenue growth (TTM)−63.3%–
Revenue growth, 5Y average–48.0%
Profitability
Operating margin−5948%–
Net margin−5594%–
FCF margin−5119%–
Return on equity−50.1% (better)−76.9%
Financial health
Debt / equity0.000.00
Current ratio21.68 (better)6.03
Altman Z-score35.70 (better)−42.52
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%23.8%
Held by insiders6.4%31.9%
Insider net buying, 12 months−$25.2M–
Short interest, % of float15.2%1.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.